AYTU Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally...

Stats
Today's Volume	13 908.00
Average Volume	20 924.00
Market Cap	15.59M
EPS	$0 ( 2024-02-14 )
Next earnings date	( $-0.640 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.0410 (1.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Pyszczymuka Greg	Buy	208	Common Shares
2024-03-31	Pyszczymuka Greg	Sell	208	Restricted Stock Units
2023-12-31	Pyszczymuka Greg	Buy	209	Common Shares
2023-12-31	Pyszczymuka Greg	Sell	209	Restricted Stock Units
2023-09-30	Pyszczymuka Greg	Buy	208	Common Shares

INSIDER POWER
30.93
Last 94 transactions
Buy: 33 552 785 \| Sell: 39 056 468

Aytu BioScience Inc Correlation

10 Most Positive Correlations
REYN	0.959
SRNGW	0.954
IBRX	0.951
VWE	0.949
HCAQ	0.948
JAGX	0.946
CHKEL	0.945
PROC	0.943
MAGS	0.942
LGMK	0.941

10 Most Negative Correlations
SMAP	-0.957
OVLY	-0.955
VAQC	-0.953
IPVIU	-0.948
SY	-0.948
GENQ	-0.948
ATEC	-0.946
HPLTU	-0.944
SJ	-0.943
IGTA	-0.943

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aytu BioScience Inc Financials

Annual	2023
Revenue:	$107.40M
Gross Profit:	$66.63M (62.04 %)
EPS:	$-5.11

Q2	2024
Revenue:	$22.93M
Gross Profit:	$16.20M (70.65 %)
EPS:	$-0.0399

Q1	2024
Revenue:	$22.10M
Gross Profit:	$14.78M (66.90 %)
EPS:	$-1.480

Q4	2023
Revenue:	$30.73M
Gross Profit:	$18.56M (60.41 %)
EPS:	$-0.590

Financial Reports:

No articles found.

Aytu BioScience Inc

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.